Immunotherapy for mouse bladder cancer by transfer of a mouse IFN-gamma cDNA
Project/Area Number |
03670752
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Urology
|
Research Institution | KYOTO UNIVERSITY |
Principal Investigator |
HASHIMURA Takayuki KYOTO University, Urology associate Prot., 医学部泌尿器科学教室, 講師 (40189478)
|
Co-Investigator(Kenkyū-buntansha) |
WATANABE Yoshihiko Kyoto University, Pharmacology Associate Prof., 助教授 (90109075)
KURIBAYASHI Kagenori Kyoto University, Immunology Assistant Prof., 助手 (10064578)
HIURA Masaru Kyoto University, Urology Assistant Prof., 助手 (20238249)
|
Project Period (FY) |
1991 – 1992
|
Project Status |
Completed (Fiscal Year 1992)
|
Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1992: ¥300,000 (Direct Cost: ¥300,000)
Fiscal Year 1991: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
Keywords | Gene therapy / Bladder cancer / IFN-gamma / Mouse bladder tumor / Immunotherapy / 遺伝子導入治療 / IFNーγ / 膀晄癌 / マウスMBTー2 |
Research Abstract |
We established constitutively IFN-gamma producing cell line(MBT2/gamma) from a mouse bladder cancer cell line(MBT2) by retroviral transfer of a mouse IFN-gamma cDNA. Although in vitro cell growth of these cells was unaffected by the IFN-gamma production, their s.c. tumor growth in syngeneic C3H/He mice was different; MBT2/gamma tumor growth was stronger suppressed(3/20) than that of MBT2(10/10). MBT2/gamma tumor growth was observed in nude mice(6/6). The mice immunized with MBT2/gamma were resistant to tumor growth of the parental cells(9/12;75%), but permitted another kind of C3H/He tumor line. These results indicate that the reduced tumorigenicity of the IFN-gamma producing line was due to the augmented specific anti-tumor immunity, probably as a result of the immunomodulatory effects of the IFN-gamma derived from the tumor.
|
Report
(3 results)
Research Products
(1 results)